Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

mber September 30, 30, 30, 30, 2011 2010 2011 2010 Millions Millions Millions Millions Share awards(1) 3.2 3.6 3.9 8.9 Convertible bonds 2.75% due 2014(2) - 33.2 - -

  1. Certain stock options have been excluded from the calculation of diluted EPS because (a) their exercise prices exceeded Shire plc's average share price during the calculation period or (b) satisfaction of the required performance/market conditions cannot be measured until the conclusion of the performance period.
  2. For the three month period ended September 30, 2010 the ordinary shares underlying the convertible bonds have not been included in the calculation of the diluted weighted average number of shares, as the effect of their inclusion would be anti-dilutive.


 

Unaudited US GAAP results for the three months to September 30, 2011

Selected Notes to the Financial Statements

(2)  Analysis of revenues

3 months to September 30, 2011 2010 2011 2011 % % of total $M $M change Revenue Net product sales: Specialty Pharmaceutical ("SP") ADHD VYVANSE 199.7 151.2 32% 18% ADDERALL XR 149.9 99.7 50% 14% INTUNIV 56.1 37.3 50% 5% EQUASYM 5.1 5.7 -11% <1% DAYTRANA - 14.7 n/a n/a 410.8 308.6 33% 38% GI LIALDA/MEZAVANT 89.7 76.0 18% 8% PENTASA 55.9 57.1 -2% 5% RESOLOR 1.5 - n/a <1% 147.1 133.1 11% 14% General products FOSRENOL 40.5 45.2 -10% 4% XAGRID(R) 23.3 20.5 14% 2% CARBATROL(R) 12.3 20.3 -39% 1% 76.1 86.0 -12% 7% Other product sales 24.0 25.3 -5% 2% Total SP product sales 658.0 553.0 19% 61% Human Genetic Therapies ("HGT") REPLAGAL 129.0 92.1 40% 12% ELAPRASE 109.6 96.8 13% 10% VPRIV 64.6 49.5 31% 6% FIRAZYR 7.2 2.9 148% <1% Total HGT product sales 310.4 241.3 29% 28% Regenerative Medicine ("RM") DERMAGRAFT 50.0 - n/a 5% Total RM product sales 50.0 - n/a 5% Total product sales 1,018.4 794.3 28% 94% Royalties: ADDERALL XR 22.9 18.0 27% 2% 3TC and ZEFFIX 17.3 40.6 -57% 2% FO
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Mich. and LIBERTYVILLE, Ill. (PRWEB) , ... ... ... NSF International, a leading provider of regulatory compliance, quality systems, analytical testing, ... LLC, a consulting firm with expertise in medical device products/processes development, design ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ... report "Gene Therapy - Technologies, Markets and Companies" ... gene therapy are difficult to estimate as there is ... marketed in China since 2004. ... The estimates are based on epidemiology of diseases to ...
(Date:9/2/2015)... Australian prostate cancer technology company Minomic International Ltd has ... science that uses its patented antibody. The ... cancer diagnostic test known as MiCheck® next year, was ... peer-reviewed Australian Museum Eureka Science Prize for Excellence ... is awarded for ground breaking research that has only ...
(Date:9/2/2015)... Biovista Inc. freut sich, ... 2015 bekanntgeben zu können. Hierbei handelt es sich ... Biovista unterstützt mit seiner Möglichkeit der Analyse ... Krankheiten als denen, für die ein Medikament ursprünglich ... Team bei der Wylder Nation Foundation bei der ...
Breaking Biology Technology:NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... Testing Market, FULLERTON, Calif., March 6 ... announced today that it has launched the ... integrated work cell which,consolidates chemistry and immunoassay ... to the company,s work cell family,combines Beckman ...
... Earlier Stage ... Chronic Kidney Disease Patients, CAMBRIDGE, Mass., March 6 ... launch of the phosphate binder,Renvela(R) (sevelamer carbonate) for dialysis patients, ... additional,approvals for the product., Genzyme has submitted a marketing ...
... SOUTH EASTON, Mass., March 6 Pressure,BioSciences, Inc. (Nasdaq: ... host,a teleconference to discuss its 2007 financial results and ... the teleconference either,by telephone or through a live web-cast. ... Wednesday March 12, 2008, Time: 4:30 p.m. Eastern ...
Cached Biology Technology:Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell 2Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients 2Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients 3Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients 4Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients 5Pressure BioSciences, Inc. to Discuss 2007 Financial Results and Provide Business Update 2
(Date:8/26/2015)... 2015 The report "Multi-Factor Authentication (MFA) ... Application (Travel & Immigration, Government, Banking, Defense, Commercial Security, ... 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is expected ... a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ages ...
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... A new study published this week in the journal ... mixing of cold, deep waters from below can change sea ... occurs in a huge region of the ocean that takes ... climate patterns, particularly global warming. Using a new measurement ...
... cell found in the trillions in our brain have made ... injury and disease such as stroke. A University of Bristol ... how astrocyte cells respond to neurological trauma. The star-shaped ... glial cell that comprise one of two main categories of ...
... research team from the School of Basic Medical ... Radix Achyranthis Bidentatae can inhibit advanced glycation end ... cortex, and improve learning and memory capabilities in ... on advanced glycation end product accumulation is associated ...
Cached Biology News:Study explains Pacific equatorial cold water region 2Study explains Pacific equatorial cold water region 3Key target responsible for triggering detrimental effects in brain trauma identified 2
... The AquaMax DW4 liquid handling system ... thorough washing all in one instrument. The ... for dispensing and plate washing96-, 384- and ... microplate washing. AquaMax DW4 has been optimized ...
... Many differences exist between the various ... of glass slide used, the length and ... targets, and the manufacturing protocol employed all ... microarray analysis. With all the different ...
... ICS-1500 system provides excellent performance with ... electrolytic suppression, and column heater all ... outstanding sensitivity and stability. The vacuum ... for trace-level work. Operate in manual ...
... Odyssey images are easily imported for data analysis , ... ... results , Extensive background and signal options to ... results , ...
Biology Products: